Stockreport

Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor? [Yahoo! Finance]

Krystal Biotech, Inc.  (KRYS) 
Last krystal biotech, inc. earnings: 11/4 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.krystalbio.com/investors
PDF therapy approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa (DEB). Krystal Biotech has made steady progress, securin [Read more]